Synthesis and properties of diadamantyl-containing symmetric diureas as target-oriented inhibitors of human soluble epoxide hydrolase
作者:V. V. Burmistrov、G. M. Butov、D. S. Karlov、V. A. Palyulin、N. S. Zefirov、C. Morisseau、B. D. Hammock
DOI:10.1134/s1068162016030067
日期:2016.7
A series of target-oriented competitive inhibitors of human solubleepoxidehydrolase have been synthesized. The compounds retain the inhibitory properties at concentrations down to 4 nM. Based on the results of molecular modeling, it has been shown that the high inhibitory activity of this series of compounds is achieved by a unique mode of the binding to the active site of the enzyme.
Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors
作者:Vladimir Burmistrov、Christophe Morisseau、Kin Sing Stephen Lee、Diyala S. Shihadih、Todd R. Harris、Gennady M. Butov、Bruce D. Hammock
DOI:10.1016/j.bmcl.2014.03.016
日期:2014.5
A series of inhibitors of the soluble epoxide hydrolase (sEH) containing two urea groups has been developed. Inhibition potency of the described compounds ranges from 2.0 mu M to 0.4 nM. 1,6-(Hexamethylene)bis[(adamant-1-yl) urea] (3b) was found to be a potent slow tight binding inhibitor (IC50 = 0.5 nM) with a strong binding to sEH (K-i = 3.1 nM) and a moderately long residence time on the enzyme (k(off) = 1.05 x 10(-3) s(-1); t(1/2) = 11 min). (C) 2014 Elsevier Ltd. All rights reserved.
Synthesis of adamantyl-containing 1,3-disubstituted diureas and thioureas, efficient targeted inhibitors of human soluble epoxide hydrolase
作者:G. M. Butov、V. V. Burmistrov、D. V. Danilov、D. A. Pitushkin、C. Morisseau、B. D. Hammock
DOI:10.1007/s11172-015-1043-y
日期:2015.7
A series of adamantyl-containing 1,3-disubstituted diureas and thioureas containing different spacers between the ureylene group and the adamantyl substituent has been synthesized, their inhibitory activity against mammalian and human soluble epoxide hydrolase (sEH, E.C. 3.3.2.10) has been examined. The compounds synthesized were found to exhibit high inhibitory activity on the 0.4–2.8 nmol L−1 level. The dependence between the inhibitor structure and its activity was established